Orbital radiation for active Graves eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether orbital (eye-socket) radiotherapy can improve active Graves’ orbitopathy, a condition that affects the eyes and eye muscles. It may help reduce eye inflammation and related symptoms if you meet the specific activity and severity criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Graves’ disease (overactive thyroid) and positive anti-TSH receptor antibodies
- You have not had thyroid surgery or radioactive iodine in the last 3 months
- Your thyroid levels are controlled (euthyroid) for at least 2 months using anti-thyroid medicine or levothyroxine
- Your Graves eye disease has been going on 1 year or less and is currently active (CAS score 3 or higher)
- You have moderate or moderately severe eye involvement and have not used steroid or other immune-suppressing treatment for eye disease in the last 3 months
- You are age 35–75 and can safely have orbital radiotherapy (no major eye or health risks like uncontrolled diabetes/retinopathy or glaucoma)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a shorter course of radiation (1 week) works as well as a standard longer course (2 weeks) for treating active thyroid eye disease that did not improve enough with steroid medicine. It may be an option if you still have eye symptoms after steroid treatment.
This trial tests whether simvastatin (a cholesterol medicine) can improve eye symptoms from Graves’ eye disease. It is aimed at people with active mild-to-moderate disease and will also check safety with blood tests, heart/skin tolerance, and stomach health.
This Phase 2 study compares sirolimus versus corticosteroids to treat active thyroid eye disease. It aims to see which treatment works better to calm eye inflammation and improve symptoms, without needing urgent eye surgery.
This study aims to build a model that helps doctors predict how thyroid eye disease (TAO) will progress, specifically for patients with moderate to severe symptoms. If you have had TAO and meet the activity criteria, your participation could lead to better personalized care.
This trial tests whether atorvastatin (a cholesterol-lowering pill) can improve active, moderate-to-severe Graves’ orbitopathy (eye swelling and bulging). It compares outcomes in people who meet specific safety and disease-activity requirements.
This study tests whether high-dose steroid pulses (given through a vein) can help people with moderate to severe Graves' eye disease that is still active. It is for people who have not yet been treated with steroids and whose eye problems began within the past year.
Hear when a new Thyroid Associated Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.